Yaping Sun | Molecular Biology | Research Excellence Award

Published on by Molecular Biologist

Dr. Yaping Sun | Molecular Biology | Research Excellence Award

Associate Senior Research Fellow | Institute of Tsinghua university in shenzhen | China

Dr. Yaping Sun is an accomplished molecular biologist and Associate Senior Research Fellow at the Institute of Tsinghua University, Shenzhen. She is internationally recognized for her contributions to protein structural biology, epigenetic regulation, and DNA polymerase engineering. Her interdisciplinary research bridges fundamental molecular mechanisms with translational biotechnology, advancing both basic biology and applied diagnostics. Dr. Sun has revealed mechanisms of parental histone inheritance, developed engineered DNA polymerases with enhanced activity, and established microfluidics-based enzyme evolution platforms. She leads competitively funded programs, with 5 published documents, 10 citations by 7 documents, and an h-index of 2.

Citation Metrics (Scopus)

100

80

60

40

20

0

Citations
10

Documents
5

h-index
2

        🟦 Citations    🟥 Documents    🟩 h-index


View Scopus Author Profile
 View Google Scholar Author Profile

Featured Publications

Essa M. Saied | Molecular Biology | Research Excellence Award

Published on by Molecular Biologist

Assoc. Prof. Dr. Essa M. Saied | Molecular Biology | Research Excellence Award 

Associate Professor | Humboldt University of Berlin | Germany

Associate Prof. Dr. Essa M. Saied is a distinguished biochemist and bioorganic chemist whose work advances synthetic medicinal chemistry, lipid biochemistry, and small-molecule drug discovery. Holding research appointments at Humboldt University of Berlin and Suez Canal University, he has built an international reputation through 72 published documents, 2,232 citations from 1,538 citing sources, and an h-index of 31. His research integrates organic synthesis, lipid biochemistry, and computational design to identify small-molecule inhibitors of key sphingolipid-metabolizing enzymes. He employs high-throughput screening, enzymatic assays, molecular modeling, and structure–activity analysis to explore biochemical pathways relevant to cancer, inflammation, and metabolic disorders. His work also develops heterocyclic scaffolds, fluorescent probes, and biochemical tools that deepen understanding of lipid signaling and enzyme function. Through editorial service, peer review, and global collaboration, he continues to contribute significantly to chemical biology and therapeutic innovation.

Profiles: Scopus | ORCID| Google Scholar

Featured Publications

Live-Cell Identification of CERT Inhibitors via NanoBRET. Angewandte Chemie, Impact Factor 16.1.

Small-Molecule Ceramidase Inhibitors: Mechanism of Action. Angewandte Chemie, Impact Factor 16.8.

Stereoselective Synthesis of Novel Sphingoid Bases. International Journal of Molecular Sciences, Impact Factor 6.21.

Subunit Composition of Serine-Palmitoyltransferase. Proceedings of the National Academy of Sciences (PNAS), Impact Factor 11.2.

Resolving Sphingolipid Isomers Using Cryogenic IR Spectroscopy. Angewandte Chemie, Impact Factor 15.3.

Shanshan Li | Molecular Biology | Excellence in Research Award

Published on by Molecular Biologist

Dr. Shanshan Li | Molecular Biology | Excellence in Research Award

Assistant Researcher | Zhejiang University | China

Dr. Shanshan Li is a dedicated researcher specializing in the chemistry, processing, and bioactivity of bee-derived products, with a strong emphasis on propolis, royal jelly, and protein–polyphenol systems. Her work bridges food chemistry, molecular biology, and functional ingredient development to uncover how processing technologies—such as ultrasound treatment and enzymatic hydrolysis—alter protein structures and enhance antioxidant, anti-inflammatory, and immunomodulatory activities. She has significantly advanced the understanding of protein–polyphenol interactions and their role in improving the functional properties of natural compounds. Dr. Li employs advanced analytical approaches, including proteomics, transcriptomics, and bioinformatics, to investigate molecular mechanisms and cellular pathways influenced by bee product components. Her research also includes comparative studies of milk fat globule membrane proteins across animal species, contributing to broader innovations in food science and bioactive ingredient development. With 998 citations across 943 documents, 50 publications, and an h-index of 21, Dr. Li has established a strong scientific presence. Her contributions support the development of health-promoting ingredients and the translation of natural bioactives into functional foods.

Profiles: Scopus

Featured Publications

Ultrasound-induced modifications in structure, antioxidant activity and functionality of whey protein isolate–propolis polyphenol conjugates. Food Chemistry.

Integrated transcriptomics and network pharmacology reveal the mechanism of poplar-type propolis on the mouse mastitis model. Nutrients.

Structural and antioxidative properties of royal jelly protein by partial enzymatic hydrolysis. Food Science and Human Wellness.

Royal jelly proteins and their derived peptides: Preparation, properties, and biological activities. Journal of Agricultural and Food Chemistry.

Milk fat globule membrane proteins among buffalo breeds via TMT proteomics. Food Research International.

 

Sooyoung Kim | Molecular Biology | Editorial Board Member

Published on by Molecular Biologist

Dr. Sooyoung Kim | Molecular Biology | Editorial Board Member

Industry | US Neurophth Therapeutics (Ex-) | United States

Soo-Young Kim is an accomplished researcher specializing in retinal biology, neurodegeneration, and therapeutic development for ocular diseases. He holds a PhD in Medicine from Korea University and has extensive experience across academia and industry, including positions at UC Irvine, Neurophth Therapeutics, ExosomePlus, Johns Hopkins Wilmer Eye Institute, and the National Eye Institute. His research focuses on retinal development, age-related macular degeneration, and neovascularization, with significant contributions to understanding photoreceptor synapse formation, retinal degeneration models, and inflammatory pathways in pathological neovascularization. Kim has authored numerous publications in high-impact journals, advancing both basic science and translational applications in ophthalmology. His work combines molecular, cellular, and whole-mount techniques to elucidate disease mechanisms and support drug evaluation, reflecting a strong commitment to bridging experimental research with therapeutic innovation.

Profile: ORCID

Featured Publications

Kim, S.-Y., Park, C. H., Moon, B.-H., & Seabold, G. K. Murine Retina Outer Plexiform Layer Development and Transcriptome Analysis of Pre-Synapses in Photoreceptors. Life, 14(9), 1103.

Moon, B.-H., Kim, Y., & Kim, S.-Y. Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment. International Journal of Molecular Sciences, 24(16), 13004.

Kim, S.-Y., & Qian, H. Comparison between sodium iodate and lipid peroxide murine models of age-related macular degeneration for drug evaluation—a narrative review. Annals of Eye Science, 7, Article 25.

Kim, S.-Y., Zhao, Y., Kim, H.-L., Oh, Y., & Xu, Q. Sodium iodate-induced retina degeneration observed in non-separate sclerochoroid/retina pigment epithelium/retina whole mounts. Annals of Eye Science, 7, Article 27.

Lee, S.-J., & Kim, S.-Y. Mouse Sclerochoroid/RPE/Retina posterior eyeball staining and Whole Mounts. BIO-PROTOCOL, 11(15), e3872.

Kim, S.-Y. Inflammatory pathways in pathological neovascularization in retina and choroid: a narrative review on the inflammatory drug target molecules in retinal and choroidal neovascularization. Annals of Eye Science, 6, Article 4.

ZHANG TING | Molecular Biology | Young Scientist Award

Published on by Molecular Biologist

Ms. ZHANG TING | Molecular Biology | Young Scientist Award 

Teacher | China Kashi University | China

Dr. Zhang Ting is a distinguished Chinese biologist specializing in biological resources, nutritional biochemistry, and translational medicine. He earned his Bachelor of Nutrition, Master’s in Nutritional Studies, and Doctor of Biology from Hoseo University, South Korea, focusing on integrative nutrition, functional foods, and systems biology. His doctoral research explored neuropharmacological mechanisms in Alzheimer’s disease, stroke, diabetes, and obesity, combining molecular assays, rodent behavioral studies, and herbal medicine bioactivity. With over a decade of laboratory experience, Zhang has worked at Hoseo University and YEJUN Institute of Biological Sciences, leading experiments on metabolic regulation, neuroprotection, and chronic disease models while mentoring junior scientists and overseeing laboratory safety. His research interests include gut-brain axis modulation, herbal and fermented food interventions, metabolic disorders, and diet-based cognitive enhancement. Zhang bridges traditional medicinal knowledge with modern translational medicine, aiming to develop innovative strategies for chronic disease mitigation. His work has been widely cited and recognized internationally, reflecting his contributions to nutritional biochemistry, neuropharmacology, and functional food research, positioning him as a rising leader in integrative biomedical science.

Profile: ORCID

Featured Publications

Zhang, T., & Park, S. (n.d.). Network pharmacology-guided discovery of traditional Chinese medicine extracts for Alzheimer’s disease: Targeting neuroinflammation and gut-brain axis dysfunction. Int J Mol Sci, 26(17), 8545. Cited by 12.

Zhang, T., & Park, S. (n.d.). Energy intake-dependent genetic associations with obesity risk: BDNF Val66Met polymorphism and interactions with dietary bioactive compounds. Antioxidants, 14(2), 170.

Zhang, T., Yue, Y., Li, C., et al. (n.d.). Vagus nerve suppression in ischemic stroke by carotid artery occlusion: Implications for metabolic regulation, cognitive function, and gut microbiome in a gerbil model. Int J Mol Sci, 25, 7831.

Zhang, T., Li, C., Yue, Y., et al. (n.d.). Fermented red pepper paste (Kochujang) modulates glucose metabolism and gut microbiota in parasympathetic suppression: Network pharmacology and in vivo study. Food Biosci, 104531.

Zhang, T., Yue, Y., Jeong, S. J., et al. (n.d.). Improvement of estrogen deficiency symptoms by long-term fermented soybeans (Doenjang) rich in Bacillus species through modulating gut microbiota in estrogen-deficient rats. Foods, 12(6), 1143.

Seyithan TAYSI | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Prof. Dr. Seyithan TAYSI | Molecular Biology | Best Researcher Award 

Professor | Gaziantep University | Turkey

Prof. Dr. Seyithan Taysi is a distinguished Professor of Medical Biochemistry at Gaziantep University, widely recognized for his pioneering work on oxidative stress, antioxidant mechanisms, free radicals, and molecular oncology. He earned his Ph.D. in Medical Biochemistry from Atatürk University, where his research on oxidative mechanisms and cellular stress regulation received the Jury’s Special Award for Best Article. Currently, he leads advanced biochemical research and teaching programs, having completed over ninety-five funded projects and holding six patents. His editorial service includes roles on international journal boards such as BioMed Research International and the International Journal of Clinical and Experimental Ophthalmology, where he has reviewed more than four hundred manuscripts. Prof. Taysi’s research focuses on oxidative and nitrosative stress, the Nrf2/Keap1 pathway, and antioxidant-based therapies, integrating biochemical and molecular approaches to improve cancer treatment and radioprotection. He has 162 documents cited by 3,969 documents, with 5,099 citations and an h-index of 39, reflecting his global influence and impact in biomedical research.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

Taysi, S., et al. Oxidative stress modulation in cancer therapy. Free Radical Biology & Medicine. Cited by 45 articles.

Taysi, S., et al. Phytotherapeutic agents against radiation-induced cellular damage. Antioxidants (Basel). Cited by 38 articles.

Taysi, S., et al. Nrf2/Keap1 pathway as a therapeutic target in oxidative diseases. Frontiers in Molecular Biosciences. Cited by 62 articles.

Taysi, S., et al. Role of antioxidants in radiotherapy protection. BioMed Research International. Cited by 55 articles.

Taysi, S., et al. Oxidative stress biomarkers in cancer patients. Clinical Biochemistry. Cited by 97 articles.

Shangze Li | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Assoc. Prof. Dr. Shangze Li | Molecular Biology | Best Researcher Award 

Assistant to the Dean | Chongqing University | China

Dr. Shangze Li (Ph.D., Associate Professor, Ph.D. Supervisor) is a distinguished researcher in the fields of antiviral innate immune signaling, inflammatory responses, and tumor biology. He is based at the School of Medicine, Chongqing University, where he leads a research group and supervises doctoral students. His work integrates advanced genetic engineering technologies such as gene knockout, knock-in approaches, and disease models to investigate the molecular basis of immune regulation and cancer development. Dr. Li has published extensively in leading international journals including Nature Communications, Cell Death and Differentiation, Cancer Research, Oncogene, and Cancer Letters, with several contributions featured in Nature Index journals. His studies have been widely cited, reflecting both scientific impact and relevance to the global biomedical community. In addition to research, he is actively involved in teaching, mentoring, editorial service, and academic leadership, contributing to the advancement of both education and medical research.

Professional Profile

Scopus

ORCID

Google Scholar

Education 

Dr. Li completed his doctoral degree in Cell Biology at Wuhan University, where he focused on the molecular mechanisms that link immune regulation to tumorigenesis. Prior to his doctoral training, he pursued two undergraduate degrees, one in Bioengineering from the Chengdu University of Technology and another in Business Administration from the University of Electronic Science and Technology of China. This unique combination of scientific and managerial education provided him with both technical expertise and leadership skills. After completing his doctorate, Dr. Li undertook postdoctoral training at the Feinberg School of Medicine, Northwestern University, where he worked on projects exploring molecular oncology, innate immunity, and translational approaches in cancer research. His diverse academic background, spanning engineering, business, molecular biology, and medical research, has prepared him to integrate interdisciplinary knowledge in his career. This foundation continues to guide his role as a scientist, supervisor, and contributor to medical and biological sciences.

Experience 

Dr. Li began his professional research career at the Feinberg School of Medicine, Northwestern University, where he served as a postdoctoral researcher in molecular oncology and immune regulation. Following this period of international training, he returned to China and accepted an appointment at Zhongnan Hospital of Wuhan University and the College of Life Sciences, where he contributed to teaching and research in biomedical sciences. He later joined the School of Medicine at Chongqing University as a faculty member, where he was subsequently promoted to Associate Professor and Ph.D. Supervisor. In this role, he leads a laboratory focused on investigating immune signaling and cancer development. In addition to his research and teaching, Dr. Li has taken on administrative responsibilities, serving as Assistant to the Dean and Deputy Director of Shared Core Facilities for Medical Research. His experience reflects a career that balances leadership, education, and internationally recognized scientific research.

Research Interests 

Dr. Li’s research centers on the molecular mechanisms of innate immune signaling, inflammation, and tumor biology. His work explores how signaling pathways regulate immune homeostasis and contribute to tumor initiation and progression. He employs genetically modified cell lines, CRISPR-based technologies, and animal models to examine the functional roles of key genes in these processes. His studies often focus on ubiquitination and deubiquitination pathways, NF-κB signaling, and the crosstalk between cellular metabolism and cell death. This approach provides critical insights into how molecular dysregulation drives oncogenesis and resistance to therapy. His research also emphasizes translational applications, identifying potential biomarkers and therapeutic strategies that may guide novel approaches in cancer treatment and immune-related diseases. By integrating molecular biology, immunology, and cancer research, Dr. Li contributes to advancing both fundamental scientific knowledge and practical innovations for improving health outcomes.

Awards 

Dr. Li’s research achievements have been recognized through broad citation and publication in top international journals. His scholarly contributions have been acknowledged in Nature Communications, Molecular Cancer, Cancer Research, and other leading journals, with some articles featured as cover stories in Nature Index publications. His body of work has earned substantial recognition in the scientific community, reflected in a strong citation record and consistent invitations to review for leading journals. He has also served as Guest Editor for Vaccines and as a reviewer for the National Natural Science Foundation of China, underscoring his role as a trusted scientific evaluator. Beyond research output, Dr. Li has contributed actively to professional organizations, including serving as a council member of the Chongqing Association of Young Scientists and participating in national academic initiatives. His record demonstrates recognition for both scholarly impact and professional service, positioning him as a strong candidate for scientific honors.

Top Noted Publications 

Dr. Li has authored more than forty peer-reviewed publications, including a substantial number as first or corresponding author. His research has appeared in high-impact journals such as Nature Communications, Molecular Cancer, Oncogene, Cancer Research, and Cancer Letters. Selected publications include Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression in Cells, CLK2 mediates NF-κB regulation in Nature Communications, Crosstalk between metabolism and cell death in tumorigenesis in Molecular Cancer, USP14 promotes colorectal cancer progression in Cell Death & Disease, and MAPK signaling and drug resistance in prostate cancer in Cancer Research. These publications reflect his long-term focus on the molecular basis of immune regulation and cancer biology. His findings have been widely cited and have advanced understanding of tumorigenesis, therapeutic resistance, and immunoregulation. Collectively, his research portfolio highlights his contributions to both fundamental science and translational medicine, strengthening his standing as an influential scholar in the field of biomedical research.

Title: Ubiquitin-Specific Protease 1 Promotes Bladder Cancer Progression
Journal: Cells
Year: 2024
Cited by: 15+

Title: CLK2 mediates IkappaBalpha-independent NF-κB regulation
Journal: Nature Communications
Year: 2024
Cited by: 30+

Title: Crosstalk between metabolism and cell death in tumorigenesis
Journal:  Molecular Cancer
Year: 2024
Cited by: 40+

Title: USP14 promotes colorectal cancer progression
Journal: Cell Death & Disease
Year: 2023
Cited by: 25+

Title: Activation of MAPK by CXCR7 causes drug resistance
Journal: Cancer Research
Year: 2019
Cited by: 200+

Conclusion

Dr. Shangze Li is a highly suitable candidate for the Best Researcher Award. His outstanding research achievements, strong academic influence, and balanced contributions to teaching, mentorship, and professional service highlight his excellence as a scholar. With continued focus on international collaboration, high-impact publications, and global leadership roles, he is exceptionally well-positioned to be recognized with this award.

Heng Zhang | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Heng Zhang | Molecular Biology | Best Researcher Award 

Lecturer | Nankai University | China

Dr. Zhang Heng is a Lecturer in Pharmacology at Nankai University, specializing in investigating the molecular mechanisms underlying malignant tumor progression and developing innovative drug therapies. He earned his B.S., M.S., and Ph.D. in Pharmaceutical Sciences from Nankai University, completing his doctoral studies with high distinction. Since joining the faculty as a lecturer, he has been actively engaged in teaching, mentoring, and advancing cutting-edge cancer research. Dr. Zhang has published multiple high-impact papers in prestigious SCI-indexed journals, including Molecular Cell, Signal Transduction and Targeted Therapy, and Advanced Materials. His scholarly contributions include original research on extrachromosomal DNA, tumor stem cell propagation, and nanomedicine-based immunotherapy. He also holds four patent applications and has received several top academic and innovation awards. Through his research and academic leadership, Dr. Zhang continues to make significant contributions toward improving the understanding of cancer biology and developing novel therapeutic strategies for clinical application.

Professional Profile

ORCID

Education

Dr. Zhang Heng pursued his higher education entirely at Nankai University, a leading institution in China recognized for excellence in pharmaceutical research. He began his academic journey with a Bachelor of Science degree in Pharmaceutical Sciences, where he built a strong foundation in pharmacology, molecular biology, and medicinal chemistry. Continuing at Nankai, he completed his Master of Science degree, focusing on the molecular biology of tumors and early drug discovery methodologies. His master’s research involved extensive laboratory experiments, including molecular cloning, protein analysis, and tumor cell line studies. Dr. Zhang then earned his Ph.D. in Pharmaceutical Sciences, conducting advanced research on the molecular mechanisms driving cancer progression and identifying new targets for therapeutic intervention. His doctoral studies resulted in multiple publications in internationally recognized journals. This academic path, marked by consistent excellence and research productivity, has equipped him with the knowledge and skills essential for his role as an independent researcher and educator.

Experience

Following the completion of his doctoral studies, Dr. Zhang Heng was appointed Lecturer at the College of Pharmacy, Nankai University. In this role, he has been responsible for delivering lectures in pharmacology, supervising undergraduate and graduate students, and leading research initiatives in molecular oncology. He has designed and managed multiple research projects, often collaborating with interdisciplinary teams, and has successfully bridged fundamental science with translational medicine. His experience encompasses conducting high-level molecular biology research, managing laboratory operations, and contributing to scientific publications as both first and corresponding author. He has filed patents for innovative drug delivery systems and tumor immunotherapies, demonstrating the applied impact of his work. Beyond laboratory research, Dr. Zhang has participated in national-level innovation competitions and academic conferences, presenting his findings to peers and experts in the field. His experience reflects a balance of teaching excellence, research innovation, and contribution to the broader scientific community.

Research Interest

Dr. Zhang Heng’s research interests lie at the intersection of cancer biology, molecular pharmacology, and drug innovation. He investigates the fundamental mechanisms that drive the malignant progression of tumors, including the role of extrachromosomal DNA, R-loop dynamics, and vasculogenic mimicry. His work also explores how specific proteins and epigenetic factors regulate tumor growth, immune evasion, and stem cell maintenance. In addition to basic research, Dr. Zhang focuses on developing new therapeutic strategies, such as tumor-targeted nanomedicines, biomimetic exosomes, and in situ tumor vaccines. He aims to integrate these novel approaches into translational medicine frameworks, ultimately leading to more effective, personalized cancer treatments. His interdisciplinary methodology combines molecular biology, pharmacology, nanotechnology, and immunotherapy, with the overarching goal of creating clinically applicable solutions for some of the most aggressive and treatment-resistant cancers. This research focus reflects both scientific curiosity and a commitment to advancing healthcare outcomes.

Award

Dr. Zhang Heng has been recognized for his outstanding research achievements, innovative contributions, and academic excellence through multiple prestigious awards. He received the Second Prize of the Tianjin Science and Technology Progress Award, which acknowledges impactful scientific advancements with practical applications. His innovative work in drug development and cancer therapy earned him the Gold Award at the China International “Internet Plus” Innovation and Entrepreneurship Competition. In recognition of his leadership, scientific merit, and contributions to society, he was awarded the Tianjin May Fourth Youth Medal. While a student, Dr. Zhang received the Zhou Enlai Scholarship, the highest honor granted by Nankai University, and was named Nankai University Student of the Year. These distinctions highlight not only his research excellence but also his dedication to innovation, community engagement, and the advancement of pharmacological sciences on both a national and international level.

Top Noted Publication

Dr. Zhang Heng has authored a series of impactful publications in high-ranking scientific journals, contributing significantly to the fields of molecular oncology and drug development. His research outputs span mechanistic cancer biology studies, novel therapeutic approaches, and the application of nanotechnology in tumor immunotherapy. These publications have been cited in multiple peer-reviewed articles, demonstrating their influence within the global scientific community. His work continues to inform and inspire ongoing research in cancer treatment innovation.

Publications list (single-line prompt):

Title: Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1–Lig3–PARylation complex
Journal: Molecular Cell
Year: 2025

Title: MTA2 triggered R-loop trans-regulates BDH1-mediated β-hydroxybutyrylation and potentiates propagation of hepatocellular carcinoma stem cells
Journal: Signal Transduction and Targeted Therapy
Year: 2021

Title: Biomimetic Immunosuppressive Exosomes that Inhibit Cytokine Storms Contribute to the Alleviation of Sepsis
Journal: Advanced Materials
Year: 2022

Title: Magnetic sculpture-like tumor cell vaccines enable targeted in situ immune activation and potent antitumor effects
Journal: Theranostics
Year: 2025

Title: Vitamin D binding protein (VDBP) hijacks Twist1 to inhibit vasculogenic mimicry in hepatocellular carcinoma
Journal: Theranostics
Year: 2024

Conclusion

Dr. Zhang Heng is a highly suitable candidate for the Research for Best Researcher Award. His combination of scientific excellence, innovation, and societal impact aligns well with the award’s criteria. With continued growth in global collaboration and academic leadership, he has the potential to become a leading figure in pharmacology and cancer research worldwide.

 

Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award

Published on by Molecular Biologist

Dr. Ingrid Tatiana Erazo | Molecular Biology | Molecular Biology Contribution Award 

Scientific Research Lead | Memorial Sloan Kettering Cancer Center | United States

Dr. Ingrid Tatiana Erazo is a distinguished cancer researcher and Scientific Research Lead at Memorial Sloan Kettering Cancer Center (MSKCC) with extensive experience in translational oncology. She earned her PhD Summa Cum Laude in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, where she pioneered research on the ERK5 signaling pathway. Her early postdoctoral work led to the discovery of the mechanism of action for ABTL-0812, an autophagy-inducing anticancer agent now in Phase III clinical trials. Over the past decade at MSKCC, she has advanced understanding of PRMT5 inhibition, therapeutic resistance, and biomarker development for precision oncology. She currently leads initiatives integrating liquid biopsy diagnostics for early cancer detection and is spearheading global health equity programs, including the creation of Brazil’s first national referral network for cancer clinical trials. Her work bridges molecular discoveries with clinical application, driving advancements in both targeted therapies and diagnostic tools.

Professional Profile

Scopus

ORCID

Google Scholar

Education

Dr. Erazo earned her PhD in Biochemistry and Molecular Biology from the Autonomous University of Barcelona, graduating Summa Cum Laude. Her doctoral research focused on dissecting the ERK5 signaling pathway and its role in cancer cell proliferation and survival. She used Tandem Affinity Purification to map ERK5’s interactome, uncovering novel noncanonical mechanisms and post-translational modifications such as SUMOylation that opened new therapeutic opportunities. Collaborating with Dana-Farber Cancer Institute at Harvard, she co-developed potent and selective ERK5 inhibitors, providing valuable pharmacological tools for cancer research. Her academic training combined molecular biology with translational oncology, giving her a unique foundation to move seamlessly from bench research to clinical applications. She also pursued advanced training in biomarker discovery and molecular diagnostics, enabling her to contribute to projects that merge fundamental discoveries with practical solutions for cancer detection, prognosis, and treatment optimization in a variety of clinical contexts.

Experience

Dr. Erazo’s professional career spans more than 20 completed research projects and leadership in multiple ongoing studies, covering molecular oncology, biomarker discovery, and therapeutic resistance. At MSKCC, she elucidated the mechanism of action of PRMT5 inhibitors and identified MUSASHI-2 as a driver of drug resistance in hematologic malignancies, leading to innovative combination therapy strategies. She developed liquid biopsy-based diagnostics for aggressive prostate cancers and integrated proteomic biomarkers into clinical research pipelines. In her earlier postdoctoral role at Ability Pharmaceuticals, she was instrumental in advancing ABTL-0812 to clinical trials by defining its mechanism and identifying relevant biomarkers. She has partnered with global pharmaceutical and biotech companies, including GlaxoSmithKline, Biodesix Inc., and Guardant Health. Her work also extends to global health initiatives, such as establishing Brazil’s first national referral network for cancer clinical trials with molecular profiling, aiming to address disparities in cancer care and ensure equitable access to precision oncology.

Research Interest

Dr. Erazo’s research focuses on cancer biology, mechanisms of drug resistance, biomarker discovery, and precision oncology. She has a particular interest in hematological malignancies and aggressive solid tumors where therapeutic resistance significantly impacts patient outcomes. Her work applies genome-wide CRISPR synthetic lethal screening, proteomics, and high-throughput drug screening to identify cancer vulnerabilities and inform new treatment strategies. She is advancing diagnostic methods through liquid biopsy technology, enabling early and non-invasive tumor detection and monitoring, with a focus on neuroendocrine prostate cancer. Dr. Erazo also addresses global health inequities by developing clinical trial networks in underrepresented regions and incorporating genetic ancestry into study designs to improve population-specific therapeutic approaches. By combining basic molecular research with translational and clinical applications, she aims to ensure that future cancer therapies and diagnostics are effective across diverse populations and accessible beyond high-resource healthcare settings.

Awards

Dr. Erazo’s scientific achievements have positioned her as a leader in translational cancer research and a nominee for the Molecular Biology Contribution Award. She is recognized for her groundbreaking work on ERK5 signaling, the clinical biomarker development for ABTL-0812, and the identification of MUSASHI-2 as a therapeutic resistance driver. Her contributions to liquid biopsy-based proteomic biomarkers for detecting lineage transformation in prostate cancer have advanced early diagnostic capabilities in precision oncology. She has also been a driving force behind the establishment of Brazil’s first national clinical trial referral network, demonstrating a strong commitment to global health equity. Her work, cited extensively in scientific literature, reflects both scientific rigor and real-world clinical impact. These accomplishments highlight her role as both a laboratory innovator and a global health strategist, whose research has shaped cancer treatment strategies and advanced diagnostic development on an international scale.

Top Noted Publications

Dr. Erazo has authored over 20 peer-reviewed articles in high-impact journals, including Annals of Oncology, Nature Communications, Autophagy, and Clinical Cancer Research. Her research spans mechanistic cancer biology, drug development, and biomarker-driven clinical applications. She has contributed to significant discoveries such as mapping the ERK5 interactome, elucidating the mechanism of action for ABTL-0812, and identifying resistance biomarkers for hematological malignancies. Her publications often emerge from collaborative projects that integrate molecular biology, pharmacology, and clinical trial data, reflecting her multidisciplinary approach to advancing oncology research. The high citation count of her work underscores its influence and the adoption of her findings by researchers and clinicians worldwide. Her studies have informed clinical trial design, therapeutic development, and diagnostic tool implementation, bridging the gap between basic science and patient-centered outcomes in cancer care.

Selected Publications (Single-Line Format)

Title: Erazo T, et al. The new antitumor drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels
Journal: Nature Communications
Cited by 312

Title: Erazo T, et al. Inhibition of PRMT5 in lymphomas overcomes therapeutic resistance via MUSASHI-2 modulation
Journal: Clinical Cancer Research
Cited by 145

Title: Erazo T, et al. ERK5 kinase activity-independent functions in cancer: implications for drug development
Journal: Autophagy
Cited by 110

Title: Erazo T, et al. Blood-based proteomic biomarkers for early detection of lineage plasticity in prostate cancer
Journal: Annals of Oncology
Cited by 35

Title: Erazo T, et al. High-throughput screening of FDA-approved drugs for novel therapeutic combinations in lymphoma
Journal: Molecular Oncology
Cited by 28

Conclusion

Dr. Ingrid Tatiana Erazo’s pioneering research, translational breakthroughs, and commitment to equitable precision oncology position her as an outstanding candidate for the Research for Molecular Biology Contribution Award. Her work exemplifies how rigorous molecular biology can directly shape novel therapeutics, diagnostics, and healthcare systems globally. Awarding her would recognize not only her individual achievements but also her vision for transforming cancer care through innovation and inclusivity.

 

Baran SEVEN | Molecular Biology | Best Paper Award

Published on by Molecular Biologist

Dr. Baran Seven | Molecular Biology | Best Paper Award

Doctorate | TST Fittings and Medical Devices Industry and Trade | Turkey

Dr. Baran Seven is a committed biologist whose academic journey reflects a deep focus on toxicology, molecular biology, and environmental sciences. He earned his undergraduate, master’s, and doctoral degrees in Biology from Giresun University. His research has primarily involved investigating the toxicological effects of various chemical compounds on in vivo models, particularly Swiss albino mice. Throughout his academic progression, he has actively participated in multiple national and international scientific projects, often examining the protective effects of natural plant extracts against induced toxicities. Dr. Seven has published extensively in peer-reviewed journals and has presented his findings at numerous scientific conferences. His work demonstrates an interdisciplinary approach, blending physiological, genetic, and biochemical methods to assess and mitigate toxicity. With a strong background in both laboratory research and academic collaboration, Dr. Seven continues to contribute significantly to the fields of environmental toxicology and biomedical sciences.

Professional Profile

Scopus

Education

Dr. Baran Seven completed his entire academic training in Biology at Giresun University, Turkey. He obtained his Bachelor’s degree in 2013, followed by a Master’s degree in 2015 under the supervision of Associate Professor Kültiğin Çavuşoğlu and Professor Kürşad Yapar. His master’s thesis, titled “Albino farelerde paraben tarafından teşvik edilen toksisiteye karşı ısırgan otu özütünün koruyucu rolünün araştırılması,” focused on evaluating the protective effects of nettle extract against paraben-induced toxicity in albino mice. Continuing his studies at the same institution, he earned his Ph.D. in 2022 with a dissertation entitled “Swiss albino farelerde sipermetrin toksisitesinin araştırılması: Fizyolojik, genetik ve biyokimyasal yaklaşım,” supervised by Professor Kültiğin Çavuşoğlu. His doctoral research took a multidisciplinary approach, analyzing cypermethrin-induced toxicity through physiological, biochemical, and genetic methodologies. This comprehensive education has provided Dr. Seven with a solid foundation in experimental biology and toxicology.

Experience

Dr. Baran Seven has contributed to several scientific projects, primarily in the capacity of assistant researcher. His experience includes laboratory-based toxicological studies involving Allium cepa root tip cells and Swiss albino mice. He played a central role in experiments examining the effects of ultraviolet radiation, parabens, heavy metals such as lead, and chemical agents like ammonium sulfate on genetic and physiological parameters. His involvement extended to analyzing the protective effects of natural substances, including Urtica dioica (nettle), Nigella sativa (black seed), carotene, and grape seed extract. Dr. Seven has also explored the antimicrobial and insecticidal properties of Pseudomonas species isolated from wastewater, contributing to the field of microbial biotechnology. He has consistently presented his findings at international and national congresses and has co-authored multiple scientific publications. His expertise spans DNA damage analysis, chromosomal aberration testing, and biochemical assessments, positioning him as a versatile and experienced researcher in biological sciences.

Research Interest

Dr. Baran Seven’s research interests focus on the fields of toxicology, genotoxicity, antioxidant mechanisms, and environmental biology. His primary research aims to evaluate the adverse effects of toxic chemicals such as cypermethrin, parabens, lead nitrate, bisphenol A, and various pesticides on biological systems. He employs animal models, particularly Swiss albino mice, and plant models like Allium cepa, to assess toxicity at genetic, biochemical, and physiological levels. A central theme in his work is the protective potential of natural compounds, including plant extracts and microbial isolates, against chemical-induced genotoxicity and oxidative stress. His methodologies include the use of comet assays, chromosomal aberration analysis, and biochemical marker evaluation to measure DNA damage and cellular response. Dr. Seven’s interdisciplinary approach allows him to contribute meaningfully to both the scientific understanding of toxic substances and the development of potential mitigation strategies using eco-friendly and natural agents.

Awards and Recognition

Although specific individual awards are not explicitly listed, Dr. Baran Seven’s academic profile demonstrates a strong pattern of recognition through conference participation and publication. He has been a consistent contributor to various prestigious scientific meetings, including the International Black Sea Congress on Environmental Sciences, Ecology Symposiums, and the International Anatolian Scientific Research Congress. His role in these conferences has often included presenting full-text research papers and co-authoring collaborative studies, signaling professional acknowledgment from the academic community. Additionally, his ongoing contributions to peer-reviewed journals and collaborative research projects underscore his growing influence in the field. The publication of his doctoral research in high-impact journals, such as Scientific Reports, is a testament to the quality and significance of his work. Dr. Seven’s consistent engagement with both national and international scientific forums indicates a promising academic trajectory and potential for future formal recognitions.

Top Noted Publications

Dr. Baran Seven has authored and co-authored several peer-reviewed articles in national and international journals, emphasizing toxicology, genotoxicity, and microbiology. Key publications include:

Title: Investigation of cypermethrin toxicity in Swiss albino mice with physiological, genetic and biochemical approaches
 Year: 2022
Cited by: 5 articles

Title: Effects of feeding genetically modified (GM) maize on oxidative stress parameters in New Zealand rabbit
 Year: 2018

Title: Insecticidal and Antimicrobial Effects of Pseudomonas Species Isolated From Waste Water
Year: 2022.

Title: Albino Farelerde Paraben Tarafından Oluşturulan Genotoksisitenin Araştırılması: Isırgan Otu Özütünün Koruyucu Rolü
Year: 2017

Conclusion

Dr. Baran Seven is a strong and suitable candidate for the Best Paper Award, especially for his Scientific Reports publication which reflects scientific rigor, interdisciplinary methodology, and public health relevance. His research outputs contribute significantly to the understanding of environmental toxicology and the protective role of natural compounds. With ongoing efforts toward high-impact dissemination and broader scientific visibility, Dr. Seven is poised to make continued valuable contributions to the field.